Leader: Uwe Sauer
Co-Leader: Andreas Hierlemann
The overall aim of NCCR AntiResist is to facilitate the development of novel anti-infective strategies. We have already initiated collaborations with several different industry partners aiming at compound screening and optimization, evaluation of non-conventional antimicrobials, defining novel antibiotic targets, and predicting pharmacokinetic/pharmacodynamics (PK/PD) in humans. Through these collaborations, we ensure early knowledge and technology transfer and gain in-depth insights in industrial requirements and opportunities.